Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort

Nephrology

Volumn 15, Issue 3, 2010, Pages 288-293

  Yong, Kenneth ^a   Kairaitis, Lukas ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Anaemia; Ferritin; Haemodialysis; Haemoglobin; Iron; Protocol

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HEALTH STATUS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFERENCE VALUE;

ANEMIA; BIOLOGICAL MARKERS; CLINICAL PROTOCOLS; COHORT STUDIES; COMMUNITY HEALTH CENTERS; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; FERRIC COMPOUNDS; FERRITINS; GUIDELINE ADHERENCE; HEMATINICS; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME; WESTERN AUSTRALIA;

EID: 77950482935     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01184.x     Document Type: Article

References (26)

1. Council of the Australian and New Zealand Society of Nephrology (ANZSN) and Kidney Health Australia (KHA). Caring for Australasians with Renal Impairment (CARI) Guidelines 2004. Available from URL: http://www.cari.org.au/ index.php
2. Irving MJ, Craig JC, Gallagher M et al. Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis. Med. J. Aust. 2006 310 314. (Pubitemid 44515432)
3. Psioni RL, Bragg-Gresham JL, Young EW et al. Anaemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). Am. J. Kidney Dis. 2004 94 111. (Pubitemid 38880932)
4. Nissenson AR, Swan SK, Lindberg JS et al. Randomised controlled trial of darbepoietin alfa for the treatment of anaemia in haemodialysis patients. Am. J. Kidney Dis. 2002 110 118.
5. Vanrenterghem Y, Barany P, Mann JFE, Kerr P, Wilson J, Baker NF, Gray SJ and on behalf of the European/Australian NESP 970200 Study Group. Randomised trial of darbepoietin-alfa for treatment of renal anaemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002 62 : 2167 2175. (Pubitemid 35366172)
6. Venables WN, Ripley BD. Modern Applied Statistics with S, 4th edn.
7. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol. Dial. Transplant. 2001 16 (Suppl 7 25 8.
8. Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Semin. Dial. 2006 19 : 146 151. (Pubitemid 43468648)
9. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anaemia in CKD: Systematic review and meta-analysis. Am. J. Kidney Dis. 2008 52 : 897 906.
10. Macdougall IC, Tucker B, Thompson J et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996 50 : 1694. (Pubitemid 26364277)
11. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am. J. Kidney Dis. 1995 25 : 41.
12. Besarab A, Amin N, Ahsan M et al. Optimisation of epoietin therapy with intravenous iron in haemodialysis patients. J. Am. Soc. Nephrol 2000 11 : 530. (Pubitemid 30115083)
13. Coyne DW, Kapoian T, Suki W et al. Ferric gluconate is highly efficacious in anaemia haemodialysis patients with high serum ferritin and low transferring saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J. Am. Soc. Nephrol 2007 18 : 975. (Pubitemid 46434515)
14. Ponka P. Cell biology of heme. Am. J. Med. Sci. 1999 318 : 241 256. (Pubitemid 30349676)
15. Fairbanks V, Beutler E. Iron deficiency. In. Beutler E, ed. Williams Haematology, 6th edn.
16. Dallman PR. Iron deficiency: Does it matter? J. Intern. Med. 1989 367 372.
17. Scrimshaw NS. Functional consequences of iron deficiency in human populations. J. Nutr. Sci. Vitaminol. (Tokyo) 1984 47 63.
18. Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anaemia of chronic kidney disease. J. Am. Soc. Nephrol. 2009 20 : 479 487.
19. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anaemia management on haemoglobin outcomes in ESRD. Am. J. Kidney Dis. 2003 111 124. (Pubitemid 36043358)
20. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol. Dial. Transplant. 2007 2129 2132. (Pubitemid 47244687)
21. Fishbane S, Berns JS. Haemoglobin cycling in haemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005 1337 1343. (Pubitemid 43246455)
22. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Haemoglobin level variability: Associations with comorbidity, intercurent events and hospitalizations. Clin. J. Am. Soc. Nephrol. 2006 1 : 1205 1210.
23. Yang W, Israni RK, Brunelli SM, Joffe M, Fishbane S, Feldman HI. Variation in haemoglobin level in patients with end stage renal disease and anaemia. J. Am. Soc. Nephrol. 2007 18 : 1364 1370.
24. Brunelli SM, Joffe MM, Israni RK et al. Marginal strucural analysis of the association between haemoglobin variability and mortality among chronic haemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008 3 : 777 782.
25. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Haemoglobin level variability: Associations with mortality. Clin. J. Am. Soc. Nephrol. 2008 133 138.
26. Brunelli SM, Lynch KE, Ankers ED et al. Assocation of haemoglobin variability and mortality among contemporary incident haemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008 3 : 1333 1340.